LU45106A1 - - Google Patents

Info

Publication number
LU45106A1
LU45106A1 LU45106DA LU45106A1 LU 45106 A1 LU45106 A1 LU 45106A1 LU 45106D A LU45106D A LU 45106DA LU 45106 A1 LU45106 A1 LU 45106A1
Authority
LU
Luxembourg
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LU45106A1 publication Critical patent/LU45106A1/xx

Links

LU45106D 1962-12-27 1963-12-23 LU45106A1 (en:Method)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP5790262 1962-12-27
JP5741963 1963-10-29
JP6427663 1963-10-29
JP6250163 1963-11-22

Publications (1)

Publication Number Publication Date
LU45106A1 true LU45106A1 (en:Method) 1964-02-24

Family

ID=27463499

Family Applications (1)

Application Number Title Priority Date Filing Date
LU45106D LU45106A1 (en:Method) 1962-12-27 1963-12-23

Country Status (5)

Country Link
BE (1) BE641880A (en:Method)
FR (1) FR3150M (en:Method)
GB (1) GB1080599A (en:Method)
LU (1) LU45106A1 (en:Method)
NL (1) NL302572A (en:Method)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2495608A1 (fr) * 1980-12-04 1982-06-11 Morelle Jean Nouveaux derives de l'acide aspartique et leurs usages
US8389576B2 (en) 2004-11-26 2013-03-05 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
DK3263100T3 (da) 2009-04-03 2020-05-11 Ocera Therapeutics Inc L-ornithinphenylacetat og fremgangsmåder til fremstilling deraf
DK2440200T3 (en) 2009-06-08 2014-12-08 Ucl Business Plc Treatment of portal hypertension in the application of l-ornithinphenylacetat
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
AU2018266357B2 (en) 2017-05-11 2022-12-08 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate
CN107540413A (zh) * 2017-09-14 2018-01-05 精晶药业股份有限公司 一种从门冬氨酸鸟氨酸结晶母液中提取尿素的方法

Also Published As

Publication number Publication date
FR3150M (fr) 1965-02-22
NL302572A (en:Method)
BE641880A (en:Method) 1964-04-16
GB1080599A (en) 1967-08-23

Similar Documents

Publication Publication Date Title
BE621553A (en:Method)
BE621626A (en:Method)
BE612190A (en:Method)
BE612847A (en:Method)
BE614159A (en:Method)
BE614532A (en:Method)
BE615523A (en:Method)
BE616785A (en:Method)
BE616839A (en:Method)
BE616904A (en:Method)
BE617475A (en:Method)
BE617902A (en:Method)
BE618561A (en:Method)
BE618790A (en:Method)
BE618896A (en:Method)
BE618984A (en:Method)
BE621469A (en:Method)
BE620090A (en:Method)
BE620230A (en:Method)
BE620262A (en:Method)
BE620360A (en:Method)
BE620371A (en:Method)
BE620399A (en:Method)
BE620490A (en:Method)
BE599783A (en:Method)